FDA Grants Second Breakthrough Nod to UTI Test Panel

FDA has granted Breakthrough Device Designation to Pattern Bioscience's investigational Urine ID/AST Panel, a diagnostic that identifies the bacteria behind a urinary tract infection and returns same-day antibiotic susceptibility results directly from a urine specimen — no culturing step required. The company announced the designation on 21 September 2026. It is Pattern's second breakthrough-designated assay, following its Pneumonia ID/AST Panel in December 2021.

What the panel does

Standard UTI workups typically culture a urine sample overnight or longer before a lab can identify the causative organism and test which antibiotics it responds to — a delay that often leaves clinicians prescribing empirically in the meantime. Pattern's Urine ID/AST Panel is built to compress that timeline: it identifies, quantifies, and phenotypically tests pathogens directly from the specimen using the company's single-cell microbiology platform, without waiting on a culture to grow. That is the same underlying approach behind the company's first breakthrough-designated product, the Pneumonia ID/AST Panel, adapted here to a different specimen type and a much higher-volume clinical workflow: urine testing is among the most common assays ordered in a clinical microbiology laboratory.

What Breakthrough Device Designation actually grants

The designation is a development and review pathway, not a market authorization. It is available to devices that offer more effective diagnosis or treatment of life-threatening or irreversibly debilitating diseases or conditions, and its practical benefit is more frequent, interactive communication with FDA reviewers during the device's development — whichever premarket route it ultimately follows, whether an IDE-supported clinical study, a 510(k), a De Novo, or a PMA — along with prioritized assignment of FDA review resources. It carries no statutory review-clock acceleration and no assurance that a clearance or approval will follow; both of Pattern's panels remain investigational, not for sale, while their respective development programs continue.

Second designation, same platform

Pattern Bioscience's first Breakthrough Device Designation, granted in December 2021, covered its Pneumonia ID/AST Panel, aimed at the same direct-from-specimen identification and susceptibility-testing problem in respiratory infections. Landing a second designation on the same core platform, this time for UTIs, signals a company strategy of extending one diagnostic architecture across multiple high-volume, sepsis-adjacent infection types rather than building separate platforms for each. For RA/QA teams watching the diagnostics-for-antimicrobial-resistance space, the pairing is also a marker of where FDA's breakthrough program has been willing to grant repeat designations to the same sponsor on a shared technology base, provided each application addresses a distinct clinical indication.

• Action: FDA Breakthrough Device Designation, an investigational-development pathway — not a clearance or approval.
• Device: Urine ID/AST Panel, direct-from-specimen UTI pathogen identification and same-day antimicrobial susceptibility testing, no culture required.
• Announced: 21 September 2026, by Pattern Bioscience.
• Precedent: the company's second breakthrough designation, after its Pneumonia ID/AST Panel (designated December 2021).
• Sponsor: Pattern Bioscience, private, Austin, Texas; Series C (2023) and Series D (2025, led by AMR Action Fund, Illumina Ventures and Omnimed Capital).

Frequently asked questions

What did FDA grant on September 21, 2026?

Breakthrough Device Designation to Pattern Bioscience's investigational Urine ID/AST Panel, a culture-free, same-day UTI pathogen identification and antibiotic susceptibility test. It is not a clearance or approval; the device is still investigational.

Why does the designation matter?

It is a voluntary FDA program offering more frequent, interactive engagement with reviewers and prioritized review resources during development of devices for life-threatening or irreversibly debilitating conditions — not an accelerated statutory clock or a guarantee of eventual clearance.

Is this Pattern Bioscience's first breakthrough designation?

No. FDA granted the company's first in December 2021, for its Pneumonia ID/AST Panel, built on the same single-cell microfluidics and machine-learning platform now adapted for urine specimens.

What is Pattern Bioscience?

A private, venture-backed diagnostics company based in Austin, Texas, founded 2016, with a Series C round announced April 2023 and a Series D round announced November 2025, plus separate U.S. government funding supporting its antimicrobial-resistance diagnostics work.